Topadur Pharma

News

8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

Read the full interview:

Download Document Dokument herunterladen Switzerland Global Enterprise Switzerland Global Enterprise

5.10.21

Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

1.7.21

Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

23.3.22

Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.